98%
921
2 minutes
20
In this study, nine -clerodane-type diterpenoids (-) were isolated from the dichloromethane extract of Bedolla & Zamudio leaves. Compounds - were new natural products, and - were acetone artifacts. In addition, four -clerodanes diterpenoids (-) previously described from different sources and six triterpenoids-identified as 3β,20,25-trihydroxylupane, oleanolic acid, 3β--acetyl-oleanolic acid, ursolic acid, 3β--acetyl-betulinic acid, and 3β,28--diacetyl-betulin-were isolated. Additionally, five flavonoids were also isolated from the methanol extract: quercetin-3--β-xylopyranosyl-(1 → 2)-β-galactopyranoside, taxifolin-7--β-glucopyranoside, naringenin-7--β-glucopyranoside, a mixture of 2 and 2 eriodictyol-7--β-glucopyranoside, caffeic acid, the methyl ester of rosmarinic acid, and rosmarinic acid. The structure of the isolated compounds was established by spectroscopic means, mainly H and C NMR, including 1D and 2D homo- and heteronuclear experiments. The absolute configuration of and was ascertained via an X-ray analysis, and that of the other compounds via ECD. The antiproliferative activity of some diterpenoids was determined using the sulforhodamine B method, where guevarain B () and 6α-hydroxy-patagonol acetonide () showed moderate activity against the K562 line, with IC (μM) = 33.1 ± 1.3 and 39.8 ± 1.5, respectively. The NO inhibition in RAW 264.7 macrophage activity was also determined for some compounds, where 2-oxo-patagonal (), 6α-hydroxy-patagonol acetonide (), and 7α-acetoxy--clerodan-3,13-dien-18,19:16,15-diolide () were proven to be active, with IC (μM) of 26.4 ± 0.4, 17.3 ± 0.5, and 13.7 ± 2.0, respectively. The chemotaxonomy of is also discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11990168 | PMC |
http://dx.doi.org/10.3390/molecules30071628 | DOI Listing |
Eur J Med Chem
August 2025
School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan, 243032, Anhui, PR China. Electronic address:
Cancer remains a leading global cause of mortality, with treatment efficacy often compromised by drug resistance, highlighting the urgent need for novel targeted therapies. The enzyme fructose-2,6-bisphosphatase 4 (PFKFB4) governs glycolytic flux by modulating fructose-2,6-bisphosphate (F2,6BP) levels. PFKFB4 overexpression has been observed in various cancers and correlates with tumor growth, aggressiveness, and poor prognosis.
View Article and Find Full Text PDFEur J Med Chem
September 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China; State Key Laboratory of Innovative Immunotherapy, Central Research Institute,
Overexpression of protein lysine methyltransferase G9a, which catalyzes mono- and di-methylation of histone H3K9 and non-histone proteins, is closely associated with poor prognosis and metastasis of various cancers. Here, we designed and synthesized a series of novel G9a inhibitors bearing 2-tetrahydroisoquinoline substituted quinazoline scaffold. Among them, compound 31 with 2-dioxole fused tetrahydroisoquinoline exhibited the most potent inhibitory effects against G9a with an IC value of 0.
View Article and Find Full Text PDFPurpose: Combinatorial therapies are essential for treating advanced non-small cell lung cancer (NSCLC), particularly overcoming resistance to third-generation epidermal growth factor receptor (EGFR) like osimertinib (OSI). The Hippo signaling pathway, a critical regulator of cell proliferation, apoptosis, and tumor progression, is often dysregulated in NSCLC and contributes to chemo-resistance. This study investigated the potential of epigallocatechin-3-gallate (EGCG), a green tea polyphenol, to overcome OSI resistance by modulating the Hippo signaling pathway, specifically through inhibition of the YAP-1 (Yes-associated protein)-TEAD (TEA domain transcription factor)-CTGF (connective tissue growth factor) axis.
View Article and Find Full Text PDFDrug Dev Res
September 2025
School of Pharmacy, The University of Jordan, Amman, Jordan.
Cancer treatment faces challenges like nonselective toxicity and drug resistance, prompting the need for innovative therapies. This study aimed to develop liposomal formulations for co-delivery of empagliflozin and rutin, evaluating their anticancer and antioxidant efficacy. PEGylated empagliflozin-loaded nanoliposomes (Empa-NLs) and empagliflozin-rutin co-loaded nanoliposomes (Empa-Rut NLs) were synthesized using the thin-film hydration technique.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
September 2025
Department of Molecular Biology and Genetics, Faculty of Science, Bartin University, Bartin, Turkey.
Schiff bases containing sulfonyl units are important compounds because of their potential biological properties in the therapeutical field. In this study, three novel ligands (L1, L2, and L3) containing the sulfonyl groups, a derivative of Schiff base, were synthesized, and their molecular structures were characterized by FT-IR, H-NMR, C NMR, and elemental analysis results. The antiproliferative activities of these Schiff base ligands were evaluated against human colon cancer (HT-29 and Caco-2) and mouse fibroblast (L929) cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method.
View Article and Find Full Text PDF